Kepivance, Macugen Approvals Are Quiet Milestones For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen's Kepivance and Pfizer/Eyetech's Macugen are the first two products approved under the new Pilot 1 "continuous marketing application" program
You may also be interested in...
Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio
The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.
Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.
Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.